Disease gougers: New Big Pharma scandal as FDA approves drug for terminal muscular dystrophy – but manufacturer hikes the price from $1,000 to $89,000 a year

A pharmaceutical company has been forced to ‘pause’ the launch of a crucial muscular dystrophy drug amid outrage over its $88,000 price-hike.

Emflaza, a steroid, is one of the only drugs believed to slow the effects of Duchenne’s muscular dystrophy (DMD), a terminal disease that disproportionately affects boys.

Until now sufferers in the US were forced to import the drug for around $1,000 since it did not have FDA approval.

Read more of the original article from DailyMail.